Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03422393Phase 1Active Not Recruiting

Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Role: lead

NCT02784834Phase 1Terminated

Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

Role: lead

NCT02611908Phase 1Withdrawn

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Role: lead

All 3 trials loaded